Cord blood ferritin and fibroblast growth factor-23 levels in neonates

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 4, 2016, Pages 1673-1679

  Ali, Farah N ^a   Josefson, Jami ^a   Mendez, Armando J ^b   Mestan, Karen ^a   Wolf, Myles ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; FIBROBLAST GROWTH FACTOR; IRON;

ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLYCEMIC INDEX; HUMAN; HUMAN EXPERIMENT; MALE; NEWBORN; NORMAL HUMAN; PARITY; RACE DIFFERENCE; TERTIARY CARE CENTER; UMBILICAL CORD BLOOD; ADULT; ANEMIA, IRON-DEFICIENCY; BLOOD; FETUS BLOOD; ILLINOIS; METABOLISM; YOUNG ADULT;

ADULT; ANEMIA, IRON-DEFICIENCY; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; FETAL BLOOD; FIBROBLAST GROWTH FACTORS; HUMANS; ILLINOIS; INFANT, NEWBORN; IRON; YOUNG ADULT;

EID: 85011300266     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3709     Document Type: Article

References (36)

1. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38-E49.
2. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
3. Wesseling-Perry K, Pereira RC, Tseng CH, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146-152.
4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
5. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737-747.
6. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:411-419.
7. Braithwaite V, Jones KS, Assar S, Schoenmakers I, Prentice A. Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children. Endocr Connect. 2014;3:1-10.
8. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793-1803.
9. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res. 2014;29:361-369.
10. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U.S.A. 2011;108:E1146-E1155.
11. Josefson JL, Zeiss DM, Rademaker AW, Metzger BE. Maternal leptin predicts adiposity of the neonate. Hormone Res Paediatr. 2014;81:13-19.
12. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957-4960.
13. Yamashita T. Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial. 2005;9:313-318.
14. Joy R, Krishnamurthy S, Bethou A, Rajappa M, Ananthanarayanan PH, Bhat BV. Early versus late enteral prophylactic iron supplementation in preterm very low birth weight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99:F105-F109.
15. Morton SB, Saraf R, Bandara DK, et al. Maternal and perinatal predictors of newborn iron status. N Z Med J. 2014;127:62-77.
16. Amiri FN, Basirat Z, Omidvar S, Sharbatdaran M, Tilaki KH, Pouramir M. Comparison of the serum iron, ferritin levels and total iron-binding capacity between pregnant women with and without gestational diabetes. J Nat Sci Biol Med. 2013;4:302-305.
17. Soubasi V, Petridou S, Sarafidis K, et al. Association of increased maternal ferritin levels with gestational diabetes and intra-uterine growth retardation. Diabetes Metab. 2010;36:58-63.
18. Zein S, Rachidi S, Awada S, et al. High iron level in early pregnancy increased glucose intolerance. J Trace Elem Med Biol. 2015;30:220-225.
19. Shields BM, Knight B, Hopper H, et al. Measurement of cord insulin and insulin-related peptides suggests that girls are more insulin resistant than boys at birth. Diabetes Care. 2007;30:2661-2666.
20. Ohata Y, Arahori H, Namba N, et al. Circulating levels of soluble alpha-Klotho are markedly elevated in human umbilical cord blood. J Clin Endocrinol Metab. 2011;96:E943-E947.
21. Takaiwa M, Aya K, Miyai T, et al. Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period. Bone. 2010;47:256-262.
22. Godang K, Froslie KF, Henriksen T, et al. Umbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates. Eur J Endocrinol. 2013;168:371-378.
23. Jaime-Perez JC, Garcia-Arellano G, Mendez-Ramirez N, Gonzalez-Llano O, Gomez-Almaguer D. Evaluation of hemoglobin performance in the assessment of iron stores in feto-maternal pairs in a high-risk population: receiver operating characteristic curve analysis. Rev Bras Hematol Hemoter. 2015;37:178-183.
24. Siddappa AM, Rao R, Long JD, Widness JA, Georgieff MK. The assessment of newborn iron stores at birth: a review of the literature and standards for ferritin concentrations. Neonatology. 2007;92:73-82.
25. David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate FGF23 production. Kidney Int. 2015; In press.
26. Baptiste-Roberts K, Salafia CM, Nicholson WK, Duggan A, Wang NY, Brancati FL. Maternal risk factors for abnormal placental growth: the national collaborative perinatal project. BMC Pregnancy Childbirth. 2008;8:44.
27. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-1378.
28. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010;95:578-585.
29. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120-6123.
30. Lindberg K, Amin R, Moe OW, et al. The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol. 2014;25:2169-2175.
31. Sakan H, Nakatani K, Asai O, et al. Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One. 2014;9:e86301.
32. Ali FN, Falkner B, Gidding SS, Price HE, Keith SW, Langman CB. Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. J Pediatr. 2014;165):738-743.
33. Prentice A. Micronutrients and the bone mineral content of the mother, fetus and newborn. J Nutr. 2003;133:1693S-1699S.
34. Bozzetti V, Tagliabue P. Metabolic bone disease in preterm newborn: an update on nutritional issues. Ital J Pediatr. 2009;35:20.
35. Kling PJ. 50 years ago in the Journal of Pediatrics:iron metabolism in premature infants: II. Prevention of iron deficiency. J Pediatr. 2014;164:768.
36. Viswanathan S, Khasawneh W, McNelis K, et al. Metabolic bone disease: a continued challenge in extremely low birth weight infants. JPEN J Parenter Enteral Nutr. 2014;38:982-990.